von Hahn Thomas, Lindenbach Brett D, Boullier Agnès, Quehenberger Oswald, Paulson Matthew, Rice Charles M, McKeating Jane A
Center for the Study of Hepatitis C, The Rockefeller University, New York, NY 10021, USA.
Hepatology. 2006 May;43(5):932-42. doi: 10.1002/hep.21139.
Cell entry of hepatitis C virus, pseudoparticles (HCVpp) and cell culture grown virus (HCVcc), requires the interaction of viral glycoproteins with CD81 and other as yet unknown cellular factors. One of these is likely to be the scavenger receptor class B type I (SR-BI). To further understand the role of SR-BI, we examined the effect of SR-BI ligands on HCVpp and HCVcc infectivity. Oxidized low-density lipoprotein (oxLDL), but not native LDL, potently inhibited HCVpp and HCVcc cell entry. Pseudoparticles bearing unrelated viral glycoproteins or bovine viral diarrhea virus were not affected. A dose-dependent inhibition was observed for HCVpp bearing diverse viral glycoproteins with an approximate IC50 of 1.5 microg/mL apolipoprotein content, which is within the range of oxLDL reported to be present in human plasma. The ability of lipoprotein components to bind to target cells associated with their antiviral activity, suggesting a mechanism of action which targets a cell surface receptor critical for HCV infection of the host cell. However, binding of soluble E2 to SR-BI or CD81 was not affected by oxLDL, suggesting that oxLDL does not act as a simple receptor blocker. At the same time, oxLDL incubation altered the biophysical properties of HCVpp, suggesting a ternary interaction of oxLDL with both virus and target cells. In conclusion, the SR-BI ligand oxLDL is a potent cell entry inhibitor for a broad range of HCV strains in vitro. These findings suggest that SR-BI is an essential component of the cellular HCV receptor complex.
丙型肝炎病毒、假病毒颗粒(HCVpp)和细胞培养产生的病毒(HCVcc)进入细胞需要病毒糖蛋白与CD81以及其他未知细胞因子相互作用。其中之一可能是B类I型清道夫受体(SR-BI)。为了进一步了解SR-BI的作用,我们研究了SR-BI配体对HCVpp和HCVcc感染性的影响。氧化型低密度脂蛋白(oxLDL)而非天然低密度脂蛋白能有效抑制HCVpp和HCVcc进入细胞。携带无关病毒糖蛋白或牛病毒性腹泻病毒的假病毒颗粒不受影响。对于携带不同病毒糖蛋白的HCVpp观察到剂量依赖性抑制,载脂蛋白含量的半数抑制浓度(IC50)约为1.5μg/mL,这在据报道存在于人体血浆中的oxLDL范围内。脂蛋白成分与靶细胞结合的能力与其抗病毒活性相关,提示其作用机制靶向宿主细胞HCV感染所必需的细胞表面受体。然而,可溶性E2与SR-BI或CD81的结合不受oxLDL影响,表明oxLDL并非简单的受体阻断剂。同时,oxLDL孵育改变了HCVpp的生物物理特性,提示oxLDL与病毒和靶细胞存在三元相互作用。总之,SR-BI配体oxLDL在体外是多种HCV毒株有效的细胞进入抑制剂。这些发现表明SR-BI是细胞HCV受体复合物的重要组成部分。